Innovation Theater 6 | Supported by: Insmed

---

Program Description

Learn about BRINSUPRI® (brensocatib), the first and only FDA-approved treatment specifically for non-cystic fibrosis bronchiectasis (NCFB), at Innovation Theater 6 on Tuesday, May 19, at 11:30 am ET. BRINSUPRI is indicated for the treatment of NCFB in adult and pediatric patients 12 years of age and older.¹

Join Dr. Maselli, a leading pulmonology expert, as he provides an overview of bronchiectasis, discusses BRINSUPRI as a treatment option, and presents key findings from the pivotal Phase 3 ASPEN trial. This session will help you to identify and diagnose bronchiectasis, and determine which patients are suitable for BRINSUPRI.

Bronchiectasis is a chronic and progressive inflammatory lung disease. Chronic neutrophilic inflammation can lead to lung function decline and an increased risk of exacerbations. BRINSUPRI targets a key driver of inflammation in bronchiectasis. In the ASPEN trial evaluating BRINSUPRI, the primary endpoint was the annualized rate of pulmonary exacerbations. This once-daily treatment option may be able to help patients with NCFB^.1-6

In addition to attending the Innovation Theater event, you can learn more about the efficacy and safety of BRINSUPRI by visiting booth 901 during ATS 2026. A variety of educational resources will be available, including interactive data presentations with clinical trial results, a real patient story, and information about the prescription process. Demonstrate your BRINSUPRI knowledge by playing the Meet the Sunrise game, and see how your patients compare to participants in the ASPEN study with an interactive tool. Printed resources will be available for you to read and keep, and staff will be on-site to answer any questions you may have. You can also explore BRINSUPRIhcp.com for information about the BRINSUPRI clinical profile, resources, and more. Insmed looks forward to seeing you at ATS 2026.

PP-BRIN-US-00604

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Dermatologic Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines
It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS
The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information.

References: 1. BRINSUPRI [package insert]. Bridgewater, NJ: Insmed Incorporated; 2025. 2. Keir HR, Chalmers JD. Semin Respir Crit Care Med. 2021;42(4):499-512. 3. Chalmers JD, et al. Nat Rev Dis Primers. 2018;4(1):45. 4. Flume PA, et al. Lancet. 2018;392(10150):880-890. 5. Chalmers JD, et al. Am J Respir Crit Care Med. 2018;197(11):1410-1420. 6. Chalmers JD, et al. Am J Respir Crit Care Med. 2017;195(10):1384-1393.

Speakers

Diego Maselli, MD, FCCP, ATSF
Professor of Medicine
Division Chief of Pulmonary Disease & Critical Care
UT Health San Antonio
San Antonio, TX